<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647255</url>
  </required_header>
  <id_info>
    <org_study_id>RESCUE</org_study_id>
    <nct_id>NCT02647255</nct_id>
  </id_info>
  <brief_title>Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy</brief_title>
  <acronym>RESCUE</acronym>
  <official_title>Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive
      immunosuppressive therapy. The efficacy of plasma exchange (PE) in CreIgAN is not well
      defined. This study will evaluate the efficacy and safety of plasma exchange as adjunctive
      therapy for severe crescentic IgA nephropathy compared to pulse methylprednisolone on a
      background of oral prednisolone and cyclophosphamide in prevent kidney failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IgA nephropathy (IgAN) is one of the most common glomerulonephritides and is characterized by
      a highly variable clinical course and diverse histopathological lesions. Although most
      affected individuals develop chronic, slowly progressive renal injury, a subgroup of patients
      (&lt;5% of all IgAN patients) with diffuse crescent formation, which is termed as crescentic IgA
      nephropathy (CreIgAN) and often leads to rapidly progressive kidney failure. The recent
      Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest high-dose steroids and
      cyclophosphamide therapy for CreIgAN. However, this suggestion is mainly based on several
      small observational studies, and the 1- and 5-year renal survival rates of patients treated
      with this regimen were as low as 65% and 28%, respectively, in one large cohort of CreIgAN
      patients. The efficacy of plasma exchange (PE) in severe CreIgAN is not well evaluated,
      although several anecdotal reports have indicated benefit of PE in combination with
      immunosuppressive therapies in IgAN patients. Retrospective cohort study in our unite also
      supported the benefit of PE as additional therapy for CreIgAN patients. However, randomized
      controlled trial is needed to evaluate the efficacy and safety of plasma exchange as
      adjunctive therapy for crescentic IgA nephropathy compared to pulse methylprednisolone on a
      background of oral prednisolone and cyclophosphamide in prevent kidney failure.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-stage renal disease or death</measure>
    <time_frame>12 months after final subject is enrolled</time_frame>
    <description>End-stage renal disease: defined as a need for maintenance dialysis &gt; 6 months; or need kidney transplantation , and death; during follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal remission</measure>
    <time_frame>12 months after final subject is enrolled</time_frame>
    <description>Renal remission: defined as the independent of dialysis, or serum creatinine under 200μmol/l within 6 months, and lasts without a first relapse until at least 12 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria remission</measure>
    <time_frame>At the 12th month and 36th month after randomization</time_frame>
    <description>Proteinuria remission: defined as proteinuria &lt; 0.5g/d for ≥3months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of serious adverse events</measure>
    <time_frame>From 12 months after first subject enrolled to 12 months after final subject is enrolled</time_frame>
    <description>Serious adverse events are defined as:
Clinically apparent gastrointestinal haemorrhage requiring hospitalization or prolonging the time of hospitalization.
Serious infections requiring hospitalization or prolonging the time of hospitalization.
Severe allergic reaction requiring hospitalization or prolonging the time of hospitalization.
Chronic viral infection, including HIV hepatitis B virus(HBV) and HCV Other adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Glomerulonephritis, IGA</condition>
  <condition>Kidney Diseases</condition>
  <condition>Acute Renal Insufficiency</condition>
  <condition>Rapidly Progressive Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>PE and methylprednisolone pulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange &gt;7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone pulse</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma Exchange (PE)</intervention_name>
    <description>PE treatment&gt;7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)</description>
    <arm_group_label>PE and methylprednisolone pulse</arm_group_label>
    <other_name>Plasmapheresis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone pulse</intervention_name>
    <description>methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod</description>
    <arm_group_label>PE and methylprednisolone pulse</arm_group_label>
    <arm_group_label>Methylprednisolone pulse</arm_group_label>
    <other_name>Intensive Immunosuppressive treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biopsy-proven within 3ws

          2. Primary IgAN or Henoch-Schönlein Purpura nephritis of crescent &gt;50%(&gt;8 glomeruli)

          3. Serum creatinine ≥ 200 μmol/l， rapidly deterioration of renal function

        Exclusion Criteria:

          1. &lt;14 or &gt;65 years old

          2. With high Scr requiring dialysis for≥ 3w

          3. Scr&gt;200μmol/L ≥1 yr before entry

          4. Main of old crescent ; Fibrous crescent&gt;50%

          5. Anti-glomerular basement membrane (GBM) or antineutrophil cytoplasmic antibody (ANCA)
             antibody positive

          6. Women in gestational and lactational period

          7. With diabetes or uncontrollable malignant hypertension or Thrombotic Microangiopathy

          8. With Malignancy

          9. Chronic active infection including HBV hepatitis C virus (HCV) HIV or active
             tuberculosis

         10. Other autoimmune disease

         11. A second clearly defined cause of renal failure

         12. Contraindication of plasma exchange treatment or steroid pulse

         13. Patients who are unlikely to comply with the study protocol in the view of the
             treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Zhang, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Renal Division, Department of Medicine, Peking University First Hospital;Peking University Institute of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renal Division, Department of Medicine, Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal division, Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://kdigo.org/home/glomerulonephritis-gn/</url>
    <description>KDIGO Clinical Practice Guideline for Glomerulonephritis (GN)</description>
  </link>
  <reference>
    <citation>Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011 Oct;22(10):1795-803. doi: 10.1681/ASN.2011050464. Epub 2011 Sep 23. Review.</citation>
    <PMID>21949093</PMID>
  </reference>
  <reference>
    <citation>Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, Wang C, Li S, Zhang J, Zhang J, Liu L, Shi S, Wang S, Chen M, Cui Z, Chen N, Yu X, Zhao M, Wang H. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013 Dec;24(12):2118-25. doi: 10.1681/ASN.2012101017. Epub 2013 Sep 12.</citation>
    <PMID>24029421</PMID>
  </reference>
  <reference>
    <citation>Abe T, Kida H, Yoshimura M, Yokoyama H, Koshino Y, Tomosugi N, Hattori N. Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin Nephrol. 1986 Jan;25(1):37-41.</citation>
    <PMID>3955907</PMID>
  </reference>
  <reference>
    <citation>Tang Z, Wu Y, Wang QW, Yu YS, Hu WX, Yao XD, Chen HP, Liu ZH, Li LS. Idiopathic IgA nephropathy with diffuse crescent formation. Am J Nephrol. 2002 Sep-Dec;22(5-6):480-6.</citation>
    <PMID>12381947</PMID>
  </reference>
  <reference>
    <citation>Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant. 2003 Jul;18(7):1321-9.</citation>
    <PMID>12808169</PMID>
  </reference>
  <reference>
    <citation>Pankhurst T, Lepenies J, Nightingale P, Howie AJ, Adu D, Harper L. Vasculitic IgA nephropathy: prognosis and outcome. Nephron Clin Pract. 2009;112(1):c16-24. doi: 10.1159/000210570. Epub 2009 Apr 3.</citation>
    <PMID>19342865</PMID>
  </reference>
  <reference>
    <citation>Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007 Jul;18(7):2180-8. Epub 2007 Jun 20.</citation>
    <PMID>17582159</PMID>
  </reference>
  <reference>
    <citation>Nicholls K, Becker G, Walker R, Wright C, Kincaid-Smith P. Plasma exchange in progressive IgA nephropathy. J Clin Apher. 1990;5(3):128-32.</citation>
    <PMID>2345159</PMID>
  </reference>
  <reference>
    <citation>Lai KN, Lai FM, Leung AC, Ho CP, Vallance-Owen J. Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature. Am J Kidney Dis. 1987 Jul;10(1):66-70. Review.</citation>
    <PMID>3300287</PMID>
  </reference>
  <reference>
    <citation>Fujinaga S, Ohtomo Y, Umino D, Mochizuki H, Murakami H, Shimizu T, Yamashiro Y, Kaneko K. Plasma exchange combined with immunosuppressive treatment in a child with rapidly progressive IgA nephropathy. Pediatr Nephrol. 2007 Jun;22(6):899-902. Epub 2007 Feb 7.</citation>
    <PMID>17285293</PMID>
  </reference>
  <reference>
    <citation>Nicholls K, Walker RG, Dowling JP, Kincaid-Smith P. &quot;Malignant&quot; IgA nephropathy. Am J Kidney Dis. 1985 Jan;5(1):42-6.</citation>
    <PMID>3966468</PMID>
  </reference>
  <reference>
    <citation>Roccatello D, Ferro M, Coppo R, Giraudo G, Quattrocchio G, Piccoli G. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant. 1995 Nov;10(11):2054-9.</citation>
    <PMID>8643167</PMID>
  </reference>
  <reference>
    <citation>Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013 Jul;28(3):145-284. doi: 10.1002/jca.21276.</citation>
    <PMID>23868759</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Hong Zhang</investigator_full_name>
    <investigator_title>Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>crescentic IgA nephropathy</keyword>
  <keyword>plasma exchange treatment or plasmapheresis</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>intensive immunosuppressive treatment</keyword>
  <keyword>methylprednisolone pulse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

